In this article
According to research conducted by Emergen Research, the global market for CAR T-cell therapy reached a size of USD 1.29 billion in 2021 and is expected to register a revenue CAGR of 24.9 percent over the forecast period. The rising incidence of cancer worldwide, growing cancer mortality rates, the rapid expansion of clinical trial activities, the proliferation of mergers and acquisitions, and the allure of initial public offerings are all identified as primary drivers of revenue growth in the global CAR T-cell therapy market. The report also generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects, while highlighting how companies are concentrating efforts on partnerships, joint ventures, product launches, and investments in research and development.
In 2021, the diffuse large B-cell lymphoma (DLBCL) segment was responsible for the majority of the rapid revenue share, as patients whose disease becomes resistant to or relapses after initial chemotherapy become strong candidates for CAR T-cell therapy, which uses the patient's own immune cells to fight the cancer. The hospital segment also accounted for a significant portion of total revenue in 2021, supported by CAR T-cell therapy's demonstrated full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia and a 40 percent full remission rate in patients with symptomatic B-cell non-Hodgkin lymphomas who had failed several prior lines of therapy. Key companies currently operating in the global CAR T-cell therapy market include Novartis AG, Pfizer Inc., CARsgen Therapeutics, Bristol-Myers Squibb, BioNTech SE, F. Hoffmann-La Roche, and Eli Lilly and Company, among others.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.